Profile of nimotuzumab in the treatment of high-grade glioma
Authors:
Open Access
- 1 April 2015
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 8, 819-825
Abstract
High-grade gliomas (HGG) are extremely aggressive lesions and represent the most common primary malignant brain tumors without an effective therapy. Standard treatment for HGG usually includes surgery followed by radiotherapy and chemotherapy. However, the prognosis of patients with HGG remains dismal. We review the humanized epidermal growth factor receptor (EGFR) and the major EGFR target drugs in HGG treatments, focusing on the EGFR antibody nimotuzumab as a new therapeutic strategy in HGG. We found that nimotuzumab with or without radiotherapy, chemotherapy in newly diagnosed or recurrent HGG, such as glioblastoma multiforme (GBM), anaplastic astrocytomas (AA), and diffuse intrinsic pontine glioma (DIPG), might improve the response rate or the survival time. In conclusion, nimotuzumab is a very well-tolerated drug with acceptable toxicity, and it may have promising value in the combination treatment. As a result, multiple center randomized controlled Phase III clinical trials need to be conducted to confirm the efficacy and toxicity for nimotuzumab in HGG.Keywords
This publication has 22 references indexed in Scilit:
- Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine gliomaNeuro-Oncology, 2014
- Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodJournal of Neuro-Oncology, 2014
- Nimotuzumab treatment of malignant gliomasExpert Opinion on Biological Therapy, 2012
- Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumabExperimental and Therapeutic Medicine, 2012
- [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].2011
- Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007.2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survivalNeuropathology and Applied Neurobiology, 2006
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.1999